Miltenyi Biomedicine Gmbh

This study is testing an experimental CAR-T cell therapy called MB-CART2019.1 in children and teenagers (6 months to under 18 years old) whose aggressive B-cell cancers have come back or have not responded to at least one prior treatment. The main goals are to see if the treatmen…

This early-stage trial is testing a new cell therapy for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to standard treatments. Doctors will collect a patient's own immune cells (T cells), genetically modify them in a lab to better …

This study is testing a personalized cell therapy for adults with a fast-growing type of lymphoma that has come back or hasn't responded to at least two prior treatments. Doctors will collect a patient's own immune cells, genetically modify them to better target the cancer, and i…

This early-stage trial is testing a new cell therapy for adults with severe, hard-to-treat autoimmune diseases like lupus, scleroderma, and muscle inflammation diseases. Doctors take a patient's own immune T-cells, genetically modify them to hunt and destroy harmful B-cells that …

This study aims to monitor the long-term safety and effectiveness of Miltenyi's CAR T cell therapies in patients who were treated at least a year ago. It will follow 40 patients with various cancers, including lymphoma, leukemia, and melanoma, to check for any late side effects a…

This early-stage trial is testing a new cell therapy called MB-CART19.1 for adults with severe systemic lupus that hasn't responded to standard treatments. The study aims to find a safe dose and see if the therapy can put lupus into remission. It involves genetically modifying a …